

Cosolvent and Dynamic Effects in Binding Pocket Search by Docking Simulations

P. Bernát Szabó,^{†,‡} Francesc Sabanes,[†] and Juan J. Nogueira^{*,‡,¶}

[†]*Quantum Chemistry and Physical Chemistry, Department of Chemistry, KU Leuven,
BE-3001 Leuven, Belgium*

[‡]*Department of Chemistry, Universidad Autónoma de Madrid, Calle Francisco Tomás y
Valiente, 7, 28049, Madrid, Spain*

[¶]*IADCHEM, Institute for Advanced Research in Chemistry, Universidad Autónoma de
Madrid, Calle Francisco Tomás y Valiente, 7, 28049 Madrid, Spain*

E-mail: juan.nogueira@uam.es

Introduction

Proteins are ubiquitous building blocks playing a critical role in the reproduction, metabolism, and regulation of living organisms and viruses. Understanding and manipulating the way proteins interact with their surrounding is, therefore, of utmost interest from both a biological and a medical point of view. Currently, the most important method to manipulate the function of proteins is through the administering of drugs. For this reason, there exist a growing interest in identifying new binders for a wide variety of proteins in the hopes of treating a number of different sicknesses.¹⁻⁷ In fact, 78 % of the biological drugs approved by the United States Food and Drug Administration (FDA) have clear protein molecular targets.⁸ Therefore, it is not surprising that scientists turned to them once again, when faced with the new and immediate challenges of the coronavirus disease 2019 (COVID-19)

pandemic.

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to claim thousands of lives every day more than a year after its outbreak.⁹ However, the knowledge about it and the developed tools to fight against it are vastly more potent than they were a year before.¹⁰ Antiviral drugs targeting the proteins vital to the reproduction of SARS-CoV-2 have been the most important tools, aside from vaccines which can only be used as preventative measures. For example, Remdesivir, one of the most widely used antiviral drugs against SARS-CoV-2 around the world,¹¹ targets the RNA-dependent RNA polymerase (RdRp) protein of the virus.¹² Furthermore, given the urgency of developing an effective treatment, most attempts to find new inhibitor substances were in fact drug repurposing studies, targeting the virus's RdRp¹³⁻¹⁷ or other important proteins.¹⁸⁻²¹ The RdRp protein is an especially promising drug target as it is responsible for the replication of the viral RNA inside the host cell,²² and it is highly similar to the RdRp of SARS-CoV,²³ which already has a number of verified inhibitors.²⁴ In addition, its high-quality three dimensional (3D) structure has been available from as early as April 2020.²⁵ In large part due to the urgent nature of the COVID-19 pandemic, most of the above cited research projects relied heavily, or even exclusively, on computational techniques for the discovery of the potential inhibitors, due to the cost and time efficiency of such methods.

High-throughput screening enables the routinely evaluation of thousands of substances in a week.²⁶ This tremendous efficacy is often supported by the development and application of innovative computational methods, which became more useful since the advent of structure-based drug design, where potential drugs are created or found based on the 3D structure of the protein target.^{27,28} Although such target structures were initially only obtainable through costly and cumbersome experimental methods, such as X-ray crystallography²⁹ or nuclear magnetic resonance (NMR) spectroscopy,³⁰ they are nowadays much more readily available due to the gradual improvement of existing methods, the appearance of new experimental methods, such as cryo-electron microscopy,³¹ and the development of recent computational

techniques, such as homology modeling.³² Taking advantage of the quickly growing body of available genomic data, computational tools capable of predicting protein structures from mere amino acid sequence information have also been developed.^{33,34} By employing one (or a combination) of the above techniques, high-quality structures are available for a larger number of protein targets than ever before.

The current challenge to computational chemists is therefore how to best utilise the available structural information. The computational methods developed for structure-based drug design fall into two main categories: *de novo* design methods construct new, tailored ligands, while docking methods select ligands complimentary to the target from the existing compound space.³⁵ Among the docking methods, virtual screening (VS) has emerged as a particularly successful technique.^{7,36} This procedure can be thought of as a computational extension to high-throughput screening, where a large number of compounds are docked to the target protein structure *in silico*. Traditionally, VS campaigns have been carried out utilising a single, experimentally determined protein structure, often in the crystallised form.^{35,37} However, the deficiencies of using only a single crystallised protein structure has been recently recognised.^{35,37-40} Firstly, the structure of the crystallised protein often differs significantly from the conformations that the protein adopts *in vivo*. Secondly, even if the crystal structure is representative of the conformation most often visited in solution, a single structure cannot account for the dynamics of protein motion.

Different theoretical models that consider the importance of protein motion have been developed, *e.g.*, the induced-fit model of ligand docking,^{41,42} where the structure of the protein may change during ligand uptake, or the model of conformational selection,⁴³⁻⁴⁵ which views the target protein as a dynamic object even in the absence of ligands. The need to take protein flexibility and motion into account became even clearer with the discovery of cryptic or hidden pocket structures.⁴⁶⁻⁴⁸ The characteristic property of these pockets is that they only appear in the presence of the appropriate ligand, while their existence is not obvious from the equilibrium structure of the protein. The exact mechanism of their formation is not

yet clear, although some combination of induced-fit and conformational selection has been hypothesised.⁴⁷ The discovery and theoretical description of such pockets are hindered by the fact that their opening often requires large scale rearrangements of the protein structure, events that are traditionally hard to predict with computational techniques.⁴⁹

With the importance of protein dynamics gaining wider recognition, new, more elaborate methods are appearing which aim to account for this phenomenon. On the one hand some of the modern computational docking programs, such as AutoDock Vina,⁵⁰ can treat a selected number of protein residues as flexible at the cost of increased calculation times. This method is well suited to study a previously known, specific binding site of the protein. However it cannot account for larger structural changes of the protein and is limited to a handful of flexible residues due to its computational requirements. On the other hand, the family of ensemble docking techniques utilises traditional (rigid protein) docking calculations in combination with an ensemble of protein conformations to account for the flexibility of the target.^{35,37} The careful selection of the structures of the ensemble can enable the description of large scale conformational changes and to the discovery of new cryptic pockets.^{45,48,49} The main challenge for these methods is the generation of the protein structure ensemble, which can be achieved experimentally by using different crystallised structures^{35,51,52} or computationally by, *e.g.*, conformational space searches,⁵³ neural networks⁵⁴ and molecular dynamics (MD).^{37,55}

MD is an especially promising avenue, after all it has been designed for the very purpose of efficiently sampling the realistic conformational space of proteins. However, one of the largest obstacle of MD calculations is the extremely slow convergence of the calculated trajectories,³⁷ which precludes the population of rarely visited conformations. Even with highly specialised code and computers the longest timescales reachable are in the range of milliseconds.⁵⁶ In order to be able to sample rare events, a number of modified MD techniques have been developed. The first group of these is the enhanced sampling methods, where some unphysical bias is introduced into the simulation in order to encourage the

sampling of otherwise unlikely conformations. Some of the most popular enhanced-sampling methods in the context of cryptic pocket discovery are umbrella sampling,⁵⁷ steered MD,⁵⁸ metadynamics,⁵⁹ and replica exchange MD,⁶⁰ among others. A completely separate approach for the sampling of rarely visited conformations harboring cryptic pockets is that of the cosolvent methods. The main idea behind these frameworks is to replace the traditional water solvent in MD simulations with a mixture of water and some other cosolvent. The oftentimes hydrophobic or amphipatic cosolvent probes can then interact with the protein and occasionally induce conformational changes or stabilise some conformations where a cryptic pocket is open. Cosolvent methods have been successfully used to identify cryptic sites in a number of targets.^{45,48,61,62}

The primary aim of the presented work is investigate the effect of protein dynamics in the results of a VS campaign. The ensemble of protein structures is obtained via MD simulations. Further sampling is obtained by cosolvent trajectories where water/benzene and water/phenol mixtures are employed. Recognising the severity of the COVID-19 pandemic, the calculations are carried out on the RdRp protein of SARS-CoV-2 and a set of FDA approved small molecule drugs, in the hopes of contributing to the generation of knowledge necessary to develop effective treatments against this virus.

Computational Details

The SARS-CoV-2 RdRp protein complex was chosen as the target of our investigations. In its active form it is composed of three domains: nonstructural proteins 7, 8 and 12 of SARS-CoV-2. Its active site is located in a deep groove and is highly similar to that of the analogous protein of the SARS-CoV.²⁴ Its simulation ready structure was obtained from the website of D. E. Shaw Research,⁶³ where extensive MD simulations have already been carried out for it. In Reference 13, the authors note that two zinc ions are necessary for the structural integrity of the protein. These ions were however not found in the structures

and trajectories downloaded from D. E. Shaw Research. After numerous failed attempts at stabilising these zinc ions in their bound positions with restraining potentials and gradual heating, their inclusion was rejected in favor of the original D. E. Shaw structure. Additionally, two crystal structures determined with cryo-electron microscopy were downloaded from the Protein Data Bank website: the apo structure 6M71⁶⁴ and the holo structure 7B3B.⁶⁵ Out of these two crystallised structures, only the apo structure was utilised for docking calculations, to emulate drug discovery VS campaigns where the holo structure of the target is not available. The holo structure was used only to visualise the conformational changes around the active site occurring during ligand binding as will be explained below.

The MD calculations were carried out with the Amber 18 program package,⁶⁶ according to the following protocol. Three types of solvent boxes were prepared for the simulations: a simple water one and two with either benzene or phenol as cosolvent. The protein structures were solvated in octahedral solvent boxes containing the appropriate mixture of water and cosolvent molecules. A distance of at least 12 Å was left between the protein and all sides of the solvent box. The charge of the system was neutralised with sodium ions. During the simulations, periodic boundary conditions and a 12 Å cutoff for the Lennard–Jones interactions were used. The solvated systems were first minimised for 1000 gradient descent steps followed by an other 1000 conjugate gradient steps. Next, the heating of the systems to 300 K were performed during a 1 ns simulation with the Langevin thermostat in the NVT ensemble. Finally, 200 ns production simulations were carried out at 300 K and 1 bar pressure using the Langevin thermostat and Berendsen barostat in the NPT ensemble. Three replicas were run for the production calculation for each solvent. The last two simulations for each solvent were started from a random equilibrated frame of the first simulation for that solvent, with the velocities of all particles randomised according to the Boltzmann-distribution. The production calculations were run with GPU acceleration, using the `pmemd` program of Amber 18.

During the preparation of the solvent boxes containing cosolvents the `packmol` program

was utilised.⁶⁷ The concentration of the cosolvents were set to 10 v/v % in both cases. In the case of the benzene cosolvent severe clustering of the cosolvent molecules was observed during the MD simulations when the default force field parameters were used. To circumvent this issue, scripts included in the **ParmEd** distribution⁶⁸ were utilised to introduce Lennard–Jones potentials between the carbon atoms of different benzene molecules.

The exact form of this artificial potential between carbon atoms i and j is:

$$V_{ij} = \gamma \left[\left(\frac{R_{\min}}{r_{ij}} \right)^{12} - 2 \left(\frac{R_{\min}}{r_{ij}} \right)^6 \right]. \quad (1)$$

Here, V_{ij} is the introduced LJ potential, γ is the parameter determining the minimum value of the potential, R_{\min} is the parameter controlling the position of the minimum, while r_{ij} is the distance between carbon atoms i and j . The default parameter values of $\gamma = 0.00036$ kcal/mol and $R_{\min} = 7.12719$ Å were utilised. After this modification was made, no clustering of the benzene molecules was observed during the simulations.

Trajectory clustering

For the clustering of the MD trajectories the **cpptraj** program⁶⁹ of Amber 18 was utilised. A density based clustering algorithm (chosen with the **dbscan** keyword of **cpptraj**) was employed, with the parameters k (unitless) and ε (in ångströms) set to 4 and 1.1 Å respectively (see Section ?? for the discussion of this choice). For each type of solvent the equilibrated part of the trajectories of the three replica simulations were concatenated and the clustering was carried out separately for each solvent. Before clustering, the structures in every frame were aligned to each other by their alpha carbon atoms. The clustering was performed using the RMSD values of the alpha carbon atoms as the distance metric between the conformations. A total of 19 cluster representatives were obtained with 13 coming from the trajectory with water as the solvent while the benzene and phenol cosolvent trajectories yielded 3 cluster representatives each.

Docking calculations

The set of FDA approved drugs were downloaded from the ZINC database⁷⁰ in the `mol2` format. This set is a popular choice for drug repurposing studies¹⁵⁻¹⁷ and with approximately 2000 thousand contained ligands, it was feasible to perform docking calculations for all protein conformation, ligand pairs. From this set, 1957 ligand structures were converted to the `pdb` format, necessary for docking with AutoDock Vina, with the `openbabel` program.⁷¹ The 19 cluster representative protein structures along with the holo crystal structure were aligned to each other by the RMSD distances between their alpha carbons. The protein and ligand structures were prepared for docking, relying on the scripts included in the AutoDockTools4 distribution.⁷² The same docking region was used for all docking calculations, which encompassed the whole protein structure and was generated by AutoDockTools4. To carry out the docking calculations, AutoDock Vina was run with the default command line options, except for the `exhaustiveness` option which was increased to 24, as is suggested by the authors for large docking regions and the `num_modes` option which was set to twenty to obtain the twenty best poses for each ligand. The parallel execution of the docking calculations were managed with in-house scripts.

Ligand similarity calculations

Based on the results of the docking calculations the best ligands binding to each discovered pocket were selected. Afterwards, similarity calculations were performed between all selected ligands. These calculations employed the RDKit program package,⁷³ using its default RDKit small molecule fingerprint and the Tanimoto similarity score.⁷⁴

Pocket description

The binding sites of the protein, discovered through computational docking calculations, were analysed with the `mdpocket` program,⁷⁵ part of the `fpocket` distribution. To this end, the

19 cluster representative protein structures were aligned to each other by their alpha carbons and concatenated to create a mock trajectory readable by `mdpocket`. The regions of space which the discovered binding pockets occupy were selected manually, by inspecting the poses of the ligands binding to the pocket in question. Based on the suggestions of the `mdpocket` authors, large regions were selected for each pocket, encompassing all or almost all docked ligand poses. With the protein structures concatenated and the binding regions selected, `mdpocket` was run with the `-S` option, instructing the program to score pockets by their druggability. Among its results `mdpocket` provides a number of pocket descriptors calculated for each frame of the supplied trajectory. From these descriptors, the pocket volume and various pocket druggability scores are utilised in the present study. To qualitatively evaluate the general druggability of a given pocket, a simple composite druggability score is defined here, that can be calculated from the descriptors provided by `mdpocket` as:

$$S = S_H + S_V + S_P + S_C . \tag{2}$$

Here, S_H , S_V , S_P and S_C are the hydrophobicity, volume, polarity and charge scores calculated by `mdpocket` respectively. It is emphasised that the definition of S is not suggested by the `mdpocket` developers and it is not intended as an absolute metric of pocket quality, but rather as a qualitative means to compare the druggability of the same pocket in different protein conformations. For more information about the calculation and meaning of the pocket descriptors utilised for S , see the `mdpocket` documentation or Reference 75.

References

- (1) Durrant, J. D.; Urbaniak, M. D.; Ferguson, M. A. J.; McCammon, J. A. Computer-Aided Identification of Trypanosoma brucei Uridine Diphosphate Galactose 4'-Epimerase Inhibitors: Toward the Development of Novel Therapies for African Sleeping Sickness. *Journal of Medicinal Chemistry* **2010**, *53*, 5025–5032.

- (2) Durrant, J. D.; Cao, R.; Gorfe, A. A.; Zhu, W.; Li, J.; Sankovsky, A.; Oldfield, E.; McCammon, J. A. Non-Bisphosphonate Inhibitors of Isoprenoid Biosynthesis Identified via Computer-Aided Drug Design. *Chemical Biology & Drug Design* **2011**, *78*, 323–332.
- (3) Li, X.; Zhang, X.; Lin, Y.; Xu, X.; Li, L.; Yang, J. Virtual Screening Based on Ensemble Docking Targeting Wild-Type p53 for Anticancer Drug Discovery. *Chemistry & Biodiversity* **2019**, *16*, e1900170.
- (4) Li, C.; Xu, L.; Wolan, D. W.; Wilson, I. A.; Olson, A. J. Virtual Screening of Human 5-Aminoimidazole-4-carboxamide Ribonucleotide Transformylase against the NCI Diversity Set by Use of AutoDock to Identify Novel Nonfolate Inhibitors. *Journal of Medicinal Chemistry* **2004**, *47*, 6681–6690.
- (5) Cosconati, S.; Hong, J. A.; Novellino, E.; Carroll, K. S.; Goodsell, D. S.; Olson, A. J. Structure-Based Virtual Screening and Biological Evaluation of Mycobacterium tuberculosis Adenosine 5'-Phosphosulfate Reductase Inhibitors. *Journal of Medicinal Chemistry* **2008**, *51*, 6627–6630.
- (6) Mullarky, E. et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. *Proceedings of the National Academy of Sciences of the United States of America* **2016**, *113*, 1778–1783.
- (7) Cosconati, S.; Forli, S.; Perryman, A. L.; Harris, R.; Goodsell, D. S.; Olson, A. J. Virtual screening with AutoDock: theory and practice. *Expert Opinion on Drug Discovery* **2010**, *5*, 597–607.
- (8) Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? *Nature Reviews. Drug Discovery* **2006**, *5*, 993–996.
- (9) Max Roser, E. O.-O., Hannah Ritchie; Hasell, J. Coronavirus Pandemic (COVID-19). *Our World in Data* **2020**, <https://ourworldindata.org/coronavirus> [Online; accessed on 21st June 2021].

- (10) Rathi, H.; Burman, V.; Datta, S. K.; Rana, S. V.; Mirza, A. A.; Saha, S.; Kumar, R. Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2. *Indian Journal of Clinical Biochemistry* **2021**, *36*, 3–22.
- (11) Rezagholizadeh, A.; Khiali, S.; Sarbakhsh, P.; Entezari-Maleki, T. Remdesivir for Treatment of COVID-19; an Updated Systematic Review and Meta-analysis. *European Journal of Pharmacology* **2021**, *897*, 173926.
- (12) Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 — Final Report. *The New England Journal of Medicine* **2020**, *383*, 1813–1826.
- (13) Ahmad, J.; Ikram, S.; Ahmad, F.; Rehman, I. U.; Mushtaq, M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study. *Heliyon* **2020**, *6*, e04502–e04502.
- (14) Ao, S.; Han, D.; Sun, L.; Wu, Y.; Liu, S.; Huang, Y. Identification of Potential Key Agents for Targeting RNA-Dependent RNA Polymerase of SARS-CoV-2 by Integrated Analysis and Virtual Drug Screening. *Frontiers in Genetics* **2020**, *11*, 581668–581668.
- (15) Ruan, Z.; Liu, C.; Guo, Y.; He, Z.; Huang, X.; Jia, X.; Yang, T. SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). *Journal of Medical Virology* **2021**, *93*, 389–400.
- (16) Kandeel, M.; Kitade, Y.; Almubarak, A. Repurposing FDA-approved phytomedicines, natural products, antivirals and cell protectives against SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase. *PeerJ (San Francisco, CA)* **2020**, *8*, e10480–e10480.
- (17) Cozac, R.; Medzhidov, N.; Yuki, S. Predicting inhibitors for SARS-CoV-2 RNA-dependent RNA polymerase using machine learning and virtual screening. [arxiv.org](https://arxiv.org/abs/2020.08.06), 2020.

- (18) Koulgi, S.; Jani, V.; Uppuladinne, M.; Sonavane, U.; Nath, A. K.; Darbari, H.; Joshi, R. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL(pro)). *Journal of Biomolecular Structure & Dynamics* **2020**, 1–21.
- (19) Guo, S.; Xie, H.; Lei, Y.; Liu, B.; Zhang, L.; Xu, Y.; Zuo, Z. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation. *Bioorganic Chemistry* **2021**, 110, 104767–104767.
- (20) Mirza, M. U.; Froeyen, M. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. *Journal Of Pharmaceutical Analysis* **2020**, 10, 320–328.
- (21) Delre, P.; Caporuscio, F.; Saviano, M.; Mangiatordi, G. F. Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease. *Frontiers in Chemistry* **2020**, 8, 594009–594009.
- (22) Xu, X.; Liu, Y.; Weiss, S.; Arnold, E.; Sarafianos, S. G.; Ding, J. Molecular model of SARS coronavirus polymerase: Implications for biochemical functions and drug design. *Nucleic Acids Research* **2003**, 31, 7117–7130.
- (23) Procacci, P.; Macchiagodena, M.; Pagliai, M.; Guarnieri, G.; Iannone, F. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations. *Chemical Communications (Cambridge, England)* **2020**, 56, 8854–8856.
- (24) Morse, J. S.; Lalonde, T.; Xu, S.; Liu, W. R. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *Chembiochem : a European Journal of Chemical Biology* **2020**, 21, 730–738.

- (25) Bucci, M. Groovy RNA polymerase Science 368, 779-782 (2020) Cell <https://doi.org/10.1016/j.cell.2020.05.034> (2020). *Nature Chemical Biology* **2020**, 16, 712–712.
- (26) Pereira, D. A.; Williams, J. A. Origin and evolution of high throughput screening. *British Journal of Pharmacology* **2007**, 152, 53–61.
- (27) Strømgaard, K., Krogsgaard-Larsen, P., Madsen, U., Eds. *Textbook of drug design and discovery*, fifth edition. ed.; CRC Press, Taylor & Francis Group: Boca Raton ; London ; New York, 2017.
- (28) Kuntz, I. D. Structure-Based Strategies for Drug Design and Discovery. *Science (American Association for the Advancement of Science)* **1992**, 257, 1078–1082.
- (29) Ilari, A.; Savino, C. *Bioinformatics: Data, Sequence Analysis and Evolution*; Humana Press: Totowa, NJ, 2008; pp 63–87.
- (30) Würz, J. M.; Kazemi, S.; Schmidt, E.; Bagaria, A.; Güntert, P. NMR-based automated protein structure determination. *Archives of Biochemistry and Biophysics* **2017**, 628, 24–32, Nuclear Magnetic Resonance.
- (31) Nwanochie, E.; Uversky, V. N. Structure Determination by Single-Particle Cryo-Electron Microscopy: Only the Sky (and Intrinsic Disorder) is the Limit. *International Journal of Molecular Sciences* **2019**, 20.
- (32) Lewis, T. E. et al. Genome3D: Exploiting structure to help users understand their sequences. *Nucleic Acids Research* **2015**, 43, D382–D386.
- (33) Parton, D. L.; Grinaway, P. B.; Hanson, S. M.; Beauchamp, K. A.; Chodera, J. D. Ensembler: Enabling High-Throughput Molecular Simulations at the Superfamily Scale. *PLoS Computational Biology* **2016**, 12, e1004728–e1004728.
- (34) AlQuraishi, M. AlphaFold at CASP13. *Bioinformatics* **2019**, 35, 4862–4865.

- (35) R.M.A, K.; I.D, K.; C.M, O. Molecular Docking to Ensembles of Protein Structures. *Journal of Molecular Biology* **1997**, *266*, 424–440.
- (36) Patrick Walters, W.; Stahl, M. T.; Murcko, M. A. Virtual screening - An overview. *Drug Discovery Today* **1998**, *3*, 160–178.
- (37) Amaro, R. E.; Baudry, J.; Chodera, J.; Demir, O.; McCammon, J. A.; Miao, Y.; Smith, J. C. Ensemble Docking in Drug Discovery. *Biophysical Journal* **2018**, *114*, 2271–2278.
- (38) Kalenkiewicz, A.; Grant, B. J.; Yang, C.-Y. Enrichment of druggable conformations from apo protein structures using cosolvent-accelerated molecular dynamics. *Biology (Basel, Switzerland)* **2015**, *4*, 344–366.
- (39) Teague, S. J. Implications of protein flexibility for drug discovery. *Nature Reviews. Drug Discovery* **2003**, *2*, 527–541.
- (40) Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design. *Molecular Pharmacology* **2000**, *57*, 213–218.
- (41) Koshland, D. E. Application of a Theory of Enzyme Specificity to Protein Synthesis. *Proceedings of the National Academy of Sciences - PNAS* **1958**, *44*, 98–104.
- (42) Jorgensen, W. L. Rusting of the Lock and Key Model for Protein-Ligand Binding. *Science (American Association for the Advancement of Science)* **1991**, *254*, 954–955.
- (43) Frauenfelder, H.; Sligar, S. G.; Wolynes, P. G. The Energy Landscapes and Motions of Proteins. *Science (American Association for the Advancement of Science)* **1991**, *254*, 1598–1603.
- (44) Tsai, C.-J.; Kumar, S.; Ma, B.; Nussinov, R. Folding funnels, binding funnels, and protein function. *Protein Science* **1999**, *8*, 1181–1190.

- (45) Uehara, S.; Tanaka, S. Cosolvent-Based Molecular Dynamics for Ensemble Docking: Practical Method for Generating Druggable Protein Conformations. *Journal of Chemical Information and Modeling* **2017**, *57*, 742–756.
- (46) Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature (London)* **2013**, *503*, 548–551.
- (47) Oleinikovas, V.; Saladino, G.; Cossins, B. P.; Gervasio, F. L. Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations. *Journal of the American Chemical Society* **2016**, *138*, 14257–14263.
- (48) Kuzmanic, A.; Bowman, G. R.; Juarez-Jimenez, J.; Michel, J.; Gervasio, F. L. Investigating Cryptic Binding Sites by Molecular Dynamics Simulations. *Accounts of Chemical Research* **2020**, *53*, 654–661.
- (49) Cimermancic, P.; Weinkam, P.; Rettenmaier, T. J.; Bichmann, L.; Keedy, D. A.; Woldeyes, R. A.; Schneidman-Duhovny, D.; Demerdash, O. N.; Mitchell, J. C.; Wells, J. A.; Fraser, J. S.; Sali, A. CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites. *Journal of Molecular Biology* **2016**, *428*, 709–719.
- (50) Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry* **2010**, *31*, 455–461.
- (51) Huang, S.; Zou, X. Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking. *Proteins, Structure, Function, and Bioinformatics* **2007**, *66*, 399–421.
- (52) Strecker, C.; Meyer, B. Plasticity of the Binding Site of Renin: Optimized Selection

- of Protein Structures for Ensemble Docking. *Journal of Chemical Information and Modeling* **2018**, *58*, 1121–1131.
- (53) Bradley, P.; Misura, K. M. S.; Baker, D. Toward High-Resolution de Novo Structure Prediction for Small Proteins. *Science (American Association for the Advancement of Science)* **2005**, *309*, 1868–1871.
- (54) Wang, A.; Zhang, Y.; Chu, H.; Liao, C.; Zhang, Z.; Li, G. Higher Accuracy Achieved for Protein-Ligand Binding Pose Prediction by Elastic Network Model-Based Ensemble Docking. *Journal of Chemical Information and Modeling* **2020**, *60*, 2939–2950.
- (55) Bolstad, E. S. D.; Anderson, A. C. In pursuit of virtual lead optimization: The role of the receptor structure and ensembles in accurate docking. *Proteins: Structure, Function, and Bioinformatics* **2008**, *73*, 566–580.
- (56) Shaw, D.; Dror, R.; Salmon, J.; Grossman, J.; Mackenzie, K.; Bank, J.; Young, C.; Deneroff, M.; Batson, B.; Bowers, K., et al. Millisecond-scale molecular dynamics simulations on Anton. ACM. IEEE Conference on Supercomputing (SC09). 2009.
- (57) Torrie, G.; Valleau, J. Nonphysical sampling distributions in Monte Carlo free-energy estimation: Umbrella sampling. *Journal of Computational Physics* **1977**, *23*, 187–199.
- (58) Gullingsrud, J. R.; Braun, R.; Schulten, K. Reconstructing Potentials of Mean Force through Time Series Analysis of Steered Molecular Dynamics Simulations. *Journal of Computational Physics* **1999**, *151*, 190–211.
- (59) Laio, A.; Gervasio, F. L. Metadynamics: a method to simulate rare events and reconstruct the free energy in biophysics, chemistry and material science. *Reports on Progress in Physics* **2008**, *71*, 126601.
- (60) Sugita, Y.; Okamoto, Y. Replica-exchange molecular dynamics method for protein folding. *Chemical Physics Letters* **1999**, *314*, 141–151.

- (61) Schmidt, D.; Boehm, M.; McClendon, C. L.; Torella, R.; Gohlke, H. Cosolvent-Enhanced Sampling and Unbiased Identification of Cryptic Pockets Suitable for Structure-Based Drug Design. *Journal of Chemical Theory and Computation* **2019**, *15*, 3331–3343.
- (62) Arcon, J. P.; Defelipe, L. A.; Lopez, E. D.; Burastero, O.; Modenutti, C. P.; Barril, X.; Marti, M. A.; Turjanski, A. G. Cosolvent-Based Protein Pharmacophore for Ligand Enrichment in Virtual Screening. *Journal of Chemical Information and Modeling* **2019**, *59*, 3572–3583.
- (63) D. E. Shaw Research, Molecular Dynamics Simulations Related to SARS-CoV-2. https://www.deshawresearch.com/downloads/download_trajectory_sarscov2.cgi/, 2020; D. E. Shaw Research Technical Data.
- (64) Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science (American Association for the Advancement of Science)* **2020**, *368*, 779–782.
- (65) Kokic, G.; Hillen, H. S.; Tegunov, D.; Dienemann, C.; Seitz, F.; Schmitzova, J.; Farnung, L.; Siewert, A.; Höbartner, C.; Cramer, P. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. *Nature Communications* **2021**, *12*, 279–279.
- (66) Case, D. A.; et al. *AMBER 18*; University of California: San Francisco, 2018.
- (67) Martínez, L.; Andrade, R.; Birgin, E. G.; Martínez, J. M. PACKMOL: A package for building initial configurations for molecular dynamics simulations. *Journal of Computational Chemistry* **2009**, *30*, 2157–2164.
- (68) Shirts, M. R. et al. Lessons learned from comparing molecular dynamics engines on the SAMPL5 dataset. *Journal of Computer-aided Molecular Design* **2017**, *31*, 147–161.
- (69) Roe, D. R.; Cheatham, T. E. PTRAJ and CPPTRAJ: Software for Processing and

- Analysis of Molecular Dynamics Trajectory Data. *Journal of Chemical Theory and Computation* **2013**, *9*, 3084–3095.
- (70) Sterling, T.; Irwin, J. J. ZINC 15 – Ligand Discovery for Everyone. *Journal of Chemical Information and Modeling* **2015**, *55*, 2324–2337.
- (71) O’Boyle, N. M.; Banck, M.; James, C. A.; Morley, C.; Vandermeersch, T.; Hutchison, G. R. Open Babel: An open chemical toolbox. *Journal of Cheminformatics* **2011**, *3*, 1–14.
- (72) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry* **2009**, *16*, 2785–2791.
- (73) RDKit: Open-source cheminformatics. <http://www.rdkit.org>, [Online; accessed 15 May 2021].
- (74) Bajusz, D.; Rácz, A.; Héberger, K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? *Journal of Cheminformatics* **2015**, *7*, 1–13.
- (75) Schmidtke, P.; Bidon-Chanal, A.; Luque, F. J.; Barril, X. MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. *Bioinformatics* **2011**, *27*, 3276–3285.